BioCentury | Oct 2, 2020
Regulation

Oct. 1 Quick Takes: Setback at FDA for Mesoblast; plus AMAG, Solid, COVID updates from Gilead, AZ and more

Bucking ODAC recommendation, FDA wants another trial from MesoblastMesoblast Ltd. (ASX:MSB; NASDAQ:MESO) said FDA issued a complete response letter to a BLA for remestemcel-L to treat pediatric steroid-refractory acute GvHD. FDA’s Oncologic Drugs Advisory Committee had voted 9...
BioCentury | Mar 25, 2019
Distillery Techniques

Stem cell-derived 3-D microvessel grafts for heart damage in cardiovascular diseases

TECHNIQUES CATEGORY: Drug platforms TECHNOLOGY: Cell therapy Rat studies suggest grafts based on a hESC-derived endothelial cell microvessel construct could help treat heart damage caused by cardiovascular diseases. Generation of the grafts involves seeding hESC-derived...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

The next wave of targets in blood cancers and hematology will come from adhesion molecules, innate immune cells and regulators of gene expression, according to BioCentury’s analysis of emerging targets at ASH 2018. BioCentury’s analysis...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Otologic

INDICATION: Hearing loss Mouse studies suggest inhibiting DDIT3 or PERK could help treat hearing loss. In a mouse model of genetic hearing loss, systemic knockout of DDIT3 decreased hearing loss compared with normal DDIT3 expression....
BioCentury | Mar 15, 2017
Distillery Therapeutics

Cardiovascular

...INDICATION: Cardiomyopathy Patient sample and mouse studies suggest inhibiting DDIT4L could help treat pathological cardiomyopathy. In...
...higher than in samples from healthy volunteers. In a DDIT4L-overexpressing mouse model of cardiac hypertrophy, DDIT4L...
...assessing the role of DDIT4L in other mouse models of heart disease. TARGET/MARKER/PATHWAY: DNA damage inducible transcript 4 like (DDIT4L; REDD2...
BioCentury | Jun 5, 2014
Targets & Mechanisms

De-stressing glaucoma

Glucocorticoids are standard of care for a host of allergic and inflammatory eye conditions, but they elevate intraocular pressure about a third of the time and can result in secondary open-angle glaucoma. A chemical chaperone...
BioCentury | May 15, 2014
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Depression DNA-damage-inducible transcript 4 (DDIT4; RTP801; REDD1) Rodent and human studies suggest inhibiting REDD1 could help treat major depressive disorder (MDD). In postmortem human prefrontal...
BioCentury | Feb 23, 2012
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology DNA-damage-inducible transcript 3 (DDIT3; CHOP10; CHOP; GADD153); x-box binding protein 1 (XBP1) Mouse studies suggest inhibiting CHOP or activating XBP1 could help treat neurodegenerative...
BioCentury | Sep 28, 2011
Financial News

Quark pulls IPO

Quark Pharmaceuticals Inc. (Fremont, Calif.) withdrew its IPO on the Tel Aviv Stock Exchange citing market conditions. The company had hoped to raise up to $55 million. Quark has two compounds in Phase II testing:...
BioCentury | Sep 22, 2011
Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Viral infection DNA-damage-inducible transcript 4 (DDIT4; RTP801; REDD1) In vitro and cell culture studies suggest inducing REDD1 expression could help...
Items per page:
1 - 10 of 26